Protein’eXpert changes name to PX’Therapeutics

The new name builds on an already strong European position as a contract research and manufacturing organization specialized in the development of recombinant biotherapeutics, the company said.

Tristan Rousselle, CEO of PX’Therapeutics, said: “Our new corporate identity better reflects our expanded mission – to provide our clients access to a high technical expertise, a flexible and efficient platform and a comprehensive approach to their therapeutic projects development.

“Moreover, one of our main objectives will remain to ensure seamless transfer from early stage R&D through to preclinical and clinical production steps.”